Unclassified · Medical Literature
[Articles] Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial
Abstract
In participants with metabolic dysfunction-associated steatohepatitis and clinically significant fibrosis, the combination of zalfermin 30 mg plus semaglutide 2·4 mg did not significantly increase the proportion of participants who had an improvement in liver fibrosis and no worsening of metabolic dysfunction-associated steatohepatitis compared with placebo by week 52. However, a nominally significant treatment effect was observed for semaglutide 2·4 mg versus placebo. Semaglutide might be considered for further clinical assessment as a potential disease-modifying therapy in the F4c population.